# Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro

**Authors:** Francesca Bietto, Elena Arranz, Beatriz Miralles, Cristina Gómez-Marín, Eva Rath, Alice J. Lucey, Linda Giblin

PMC · DOI: 10.3389/fnut.2025.1577369 · 2025-06-09

## TL;DR

Researchers developed a temporary infant-like gut barrier model using sodium glycodeoxycholate, which helps study early life gut physiology and nutrient absorption.

## Contribution

A novel in vitro model using sodium glycodeoxycholate to mimic infant gut permeability without inflammation is introduced.

## Key findings

- GDC treatment increases paracellular permeability and reduces TEER without causing inflammation or cytotoxicity.
- 0.8 mM GDC increased lactulose transport and altered tight junction proteins and mucin production.
- GDC-treated monolayers showed enhanced amino acid absorption from infant formula.

## Abstract

In newborns, the intestinal barrier is permeable but not inflamed. Understanding this unique state is essential for developing models relevant to infant gut physiology.

This study aimed to develop an in vitro model of the infant gut barrier treating Caco-2/HT29-MTX with 0.5, 0.8, and 1 mM sodium glycodeoxycholate (GDC).

Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. Notably, the treatment with 0.8 mM GDC increased lactulose transport rate by 1.63-fold. The treatment also reduced the key tight junction protein, occludin, at the cell membrane, and increased acidic mucins and extracellular alkaline phosphatase activity. Additionally, GDC decreased cAMP, suggesting its mechanism of action was via activation of a G-protein coupled receptor. Of particular importance to nutrition studies, the GDC effect was reversible with TEER recovery within 4 h. Applying digested infant formula to 0.8 mM GDC-treated Caco-2/HT29-MTX monolayers resulted in a higher concentration of amino acids in the basolateral compartment compared to control monolayers.

These findings suggest that GDC can modulate gut barrier properties in a controled, reversible manner, offering a valuable model for studying nutrient absorption and gut physiology in early life.

Created with BioRender.com.

## Linked entities

- **Proteins:** si:ch73-61d6.3 (uncharacterized si:ch73-61d6.3)
- **Chemicals:** sodium glycodeoxycholate (PubChem CID 23688465), lactulose (PubChem CID 11333), cAMP (PubChem CID 6076)

## Full-text entities

- **Genes:** OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}
- **Diseases:** inflammation (MESH:D007249), cytotoxicity (MESH:D064420)
- **Chemicals:** GDC (MESH:D006002), MTX (-), lactulose (MESH:D007792), amino acids (MESH:D000596)
- **Cell lines:** Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), HT29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), MTX — Homo sapiens (Human), Transformed cell line (CVCL_B3BL)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12184380/full.md

---
Source: https://tomesphere.com/paper/PMC12184380